Precision biosciences stock.

Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is ...

Precision biosciences stock. Things To Know About Precision biosciences stock.

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to ...Precision BioSciences, Inc. (DTIL) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 0.3650 +0.0099 (+2.79%) At close: 04:00PM EST. 0.3798 +0.01 (+4.05%) After hours: 06 ...Nov 24, 2023 · Precision Biosciences Inc (NASDAQ:DTIL)’s traded shares stood at 0.64 million during the latest session, with the company’s beta value hitting 1.50. At the last check today, the stock’s price was $0.41, to imply a decrease of -3.21% or -$0.01 in intraday trading. The DTIL share’s 52-week ... Nov 29, 2023

Precision Biosciences, Inc. Condensed Balance Sheets Data (In thousands, except share amounts) (Unaudited) June 30, 2023: December 31, 2022: Cash and cash equivalents $ 137,794 $ 189,576 Working capital 91,465 139,441 Total assets 181,697 238,169 Total liabilities 147,656 177,736 Total stockholders' equity $ 34,041 $ 60,433 Common stock outstandingPrecision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.

Jun 27, 2022 · DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds ... We would like to show you a description here but the site won’t allow us.

Precision BioSciences, Inc. (Nasdaq: DTIL) will present at Hep-DART 2023 in Los Cabos, Mexico, showcasing their PBGENE-HBV Program for gene editing ...Precision Biosciences Stock Earnings. The value each DTIL share was expected to gain vs. the value that each DTIL share actually gained. Precision Biosciences ( DTIL) reported Q3 2023 earnings per share (EPS) of -$0.14, beating estimates of -$0.18 by 21.37%. In the same quarter last year, Precision Biosciences 's earnings per share (EPS) was ...JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $4.00.The company’s shares closed today at $0.85. Roy ...Get Precision BioSciences, Inc. (DTIL) real-time share value, investment, rating and financial market information from Capital. Friendly Platforms & Trading today. CFDs are …

Aug 7, 2023 · DURHAM - Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced financial results for the second quarter ended June 30, 2023 and provided a business update.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...

Tuesday, April 18, 2023. Precision Biosciences Expects Approximately $158M In Cash And Cash Equivalents As Of March 31, 2023. The Company's Management Also Believes That The Existing Cash And Cash ...Nov 14, 2019 · Shares of Precision BioSciences (DTIL 0.23%) ... As of 1:40 p.m. EST, the stock had settled to a 16.9% gain. The gene-editing stock is up 70% since the beginning of November. Precision Biosciences Inc (NASDAQ:DTIL)’s traded shares stood at 0.64 million during the latest session, with the company’s beta value hitting 1.50. At the last check today, the stock’s price was $0.41, to imply a decrease of -3.21% or -$0.01 in intraday trading. The DTIL share’s 52-week ...Precision BioSciences (DTIL) JonesTrading analyst Soumit Roy reiterated a Buy rating on Precision BioSciences today and set a price target of $4.00. The company’s shares closed last Wednesday at ...Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and ...Nov 24, 2023 · Checkpoint Therapeutics (NASDAQ:CKPT) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. The Precision BioSciences Inc. stock price fell by -9.31% on the last day (Wednesday, 29th Nov 2023) from $0.408 to $0.370. During the last trading day the stock fluctuated 15.44% from a day low at $0.360 to a day high of $0.416. The price has risen in 6 of the last 10 days and is up by 6.78% over the past 2 weeks.

Dec 1, 2023 · About the Company. Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. Precision BioSciences, Inc. Common Stock (DTIL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Shares of Precision BioSciences (DTIL 0.23%) ... As of 1:40 p.m. EST, the stock had settled to a 16.9% gain. The gene-editing stock is up 70% since the beginning of November.Precision BioSciences, Inc. Common Stock (DTIL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.May 31, 2023 · In a report released today, Justin Zelin from BTIG maintained a Buy rating on Precision BioSciences ( DTIL – Research Report ), with a price target of $6.00. The company’s shares opened today ...

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments.DURHAM, N.C.-June 21, 2022 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with …

Find the latest Precision BioSciences, Inc. (DTIL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. Mullen Automotive, Inc. Common Stock. $0.2205 +0.0496 29.02%. Precision BioSciences, Inc. Common Stock (DTIL) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US ... June 23, 2022 at 12:08 PM · 3 min read. Shares of Precision BioSciences, Inc. DTIL have remained up so far this week as the company has entered into an exclusive worldwide in vivo gene-editing ...Mullen Automotive, Inc. Common Stock. $0.2205 +0.0496 29.02%. Precision BioSciences, Inc. Common Stock (DTIL) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US ... Alberta Precision Labs (APL) is a medical laboratory that offers a wide range of diagnostic tests and services. If you need to book an appointment with APL, there are a few things you should know before you go.On November 7, 2023, Precision BioSciences Inc (NASDAQ:DTIL), an advanced gene editing company, announced its financial results for the third quarter ended September 30, 2023. The company reported ...Analysts Just Published A Bright New Outlook For Precision BioSciences, Inc.'s (NASDAQ:DTIL) Simply Wall St. August 6, 2023 at 5:03 AM · 2 min read. Celebrations may be in order for Precision ...If you’ve scheduled an appointment at Alberta Precision Labs, you’re taking a proactive step towards managing your health. Whether it’s for routine blood work or a specific test, it’s important to prepare for your appointment to ensure the ...Read Next: Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications. Price Action: DTIL stock is up 5.54% at $13.33 during the market session on the last check Thursday. SHARE ...8 thg 3, 2019 ... Precision BioSciences Stock Offered in IPO · Unwanted on- and off-target DNA modifications. · Inability to efficiently and precisely introduce ...

Precision BioSciences (Nasdaq:DTIL) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech Precision …

Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ...

Get the latest information on Precision BioSciences Inc (DTIL), a biotechnology company that develops and commercializes genomic tests for cancer and other diseases. See its stock price, performance, financials, outlook, and news on Google Finance. Based on short-term price targets offered by five analysts, the average price target for Precision BioSciences comes to $3.00. The forecasts range from a low of $1.00 to a high of $5.00. The ...Precision BioSciences Inc. 0.3787. Delayed Data. As of Nov 10. -0.0153 / -3.88%. Today’s Change. 0.28. Today ||| 52-Week Range.You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.13 thg 4, 2021 ... Do you want to earn up to a 4888583% annual return on your money by two trades per day on Precision Biosciences Inc DTIL Stock? Reading this ...DURHAM, N.C.--(BUSINESS WIRE)--Jun. 8, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced its latest program updates across its allogeneic CAR T pipeline. The Company provided new …Precision BioSciences (NASDAQ: DTIL), a biotechnology firm focusing on gene editing, announced that on November 21, the company's Compensation Committee authorized an inducement stock option for a new hire under the Nasdaq Listing Rule 5635(c)(4). The inducement, part of their Inducement Award Plan, allows the employee …Analysts Just Published A Bright New Outlook For Precision BioSciences, Inc.'s (NASDAQ:DTIL) Simply Wall St. August 6, 2023 at 5:03 AM · 2 min read. Celebrations may be in order for Precision ...

4 ngày trước ... Precision BioSciences Inc (DTIL:NASDAQ CM) の株価、株式情報、チャート、関連ニュースなど、企業概要や株価の分析をご覧いただけます。Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled “ Efficient elimination of MELAS-associated m ...Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $4.00.The company’s shares opened today at $0.57. Roy ...Instagram:https://instagram. fha mortgage rates aztrinity industries incanhaiser bushis apis cor a good investment Jun 21, 2022 · DURHAM, N.C.--(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately ... Precision Biosciences Inc. Watch list NEW Set a price target alert Open Last Updated: Dec 1, 2023 9:53 a.m. EST Real time quote $ 0.3645 0.0094 2.65% Previous Close $0.3551 Advanced Charting... nasdaq minimost trusted gold sellers Aug 15, 2023 · DURHAM, N.C., August 15, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced completion ... what are the most valuable quarters Precision BioSciences (NASDAQ: DTIL ), a biotechnology firm focusing on gene editing, announced that on November 21, the company's Compensation Committee authorized an inducement stock option for ...Precision BioSciences market cap as of November 07, 2023 is $0.05B . Precision BioSciences market cap history and chart from 2018 to 2023. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares ...